Magraner J, Pinto F M, Anselmi E, Hernandez M, Perez-Afonso R, Martín J D, Advenier C, Candenas M L
Departament de Farmacología, Facultat de Farmàcia, Universitat de València, Spain.
Br J Pharmacol. 1998 Jan;123(2):259-68. doi: 10.1038/sj.bjp.0701613.
1 The aim of our study was to characterize the tachykinin receptor population in the oestrogen-primed rat uterus. For this purpose, we investigated the receptor type(s) responsible for tachykinin-induced contraction of longitudinally-arranged smooth muscle layer. The effects of substance P (SP), neurokinin A (NKA), neurokinin B (NKB) and several of their analogues with well-defined selectivities for tachykinin NK1, NK2 and NK3 receptors were studied and their inhibition by the selective nonpeptide tachykinin receptor antagonists (S)1-(2-[3-(3,4-dichlorophenyl)-1-(3-isopropoxyphenylacetyl)pip eridin-3-yl]ethyl)-4-phenyl- -azoniabicyclo[2.2.2]octane chloride (SR 140333, NK1-selective), (S)-N-methyl-N[4-(4acetylamino-4-phenylpiperidino)-2-(3,4-dichloro phenyl)butyl]benzamide (SR 48968, NK2-selective) and (R)-(N)-(1-(3-(1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl)prop yl)-4-phenylpiperidin-4-yl)-N- methyla-cetamide (SR 142801, NK3-selective) was evaluated. Additionally, expression of tachykinin receptor mRNA was examined by using the reverse transcription-polymerase chain reaction (RT-PCR). 2 SP, NKA, [Nle10]-NKA(4-10), the analogue with selectivity at the tachykinin NK2 receptor type, and NKB elicited concentration-dependent contractions of the rat uterus. The pD2 values were 5.95+/-0.19; 6.73+/-0.21; 7.53+/-0.12 and 5.76+/-0.21, respectively. The selective agonist for the tachykinin NK1 receptor [Sar9Met(O2)11]-SP produced a small phasic response in the nanomolar concentration range. The selective tachykinin NK3 receptor agonist [MePhe7]-NKB failed to induce any significant contraction. 3 In the presence of the neutral endopeptidase inhibitor phosphoramidon (1 microM), the log concentration-response curves to exogenous tachykinins and their analogues were shifted significantly leftwards. The pD2 values were 6.12+/-0.10, 8.04+/-0.07, 7.89+/-0.03 and 6.59+/-0.07 for SP, NKA, [Nle10]-NKA(4-10) and NKB, respectively. In the presence of phosphoramidon (1 microM), [Sar9Met(O2)11]-SP (1 nM - 0.3 microM) induced concentration-dependent contractions of increasing amplitude when only one concentration of drug was applied to each uterine strip and the pD2 value was 7.61+/-0.89. [MePhe7]-NKB induced small, inconsistent contractions and, therefore, a pD2 value could not be calculated. 4 In experiments performed in the presence of phosphoramidon (1 microM), SR 48968 (3 nM - 0.1 microM) caused parallel and rightward shifts in the log concentration-response curves of NKA. The calculated pKB value was 9.16+/-0.08 and the slope of the Schild regression was 1.28+/-0.24. SR 48968 (0.1 microM) also antagonized responses to SP with an apparent pKB value of 7.63+/-0.13. SR 48968 (0.1 microM) inhibited contractions elicited by NKB (1 nM - 3 microM) and [Nle10]-NKA(4-10) (0.1 nM - 3 microM) but had no effect on the response evoked by [Sar9Met(O2)11]-SP (0.1 microM). 5 SR 140333 (0.1 microM) inhibited responses to SP with an apparent pKB value of 7.19+/-0.22. This compound did not significantly affect responses to NKA, [Nle10]-NKA(4-10) and NKB, but suppressed [Sar9Met(O2)11]-SP (0.1 microM)-induced contraction. SR 142801 (0.1 microM) had no effect on responses to natural tachykinins or their analogues. 6 Total RNA was extracted from some of the uteri used in functional studies. RT-PCR assays revealed single bands corresponding to the expected product sizes encoding cDNA for tachykinin NK1 (587 base pairs) and NK2 receptors (491 base pairs) (n=6 different animals). A very low abundance transcript corresponding to the 325 base pairs product expected for the tachykinin NK3 receptor was detected. 7 The present data show that functionally active tachykinin NK1 and NK2 receptors are expressed in the oestrogen-primed rat uterus. The NK2 receptor type seems to be the most important one involved in the contractile responses elicited by tachykinins. NK3 receptors are present in trace amounts and seem not to be involved in tachykinin-induced contractions.
1 我们研究的目的是表征雌激素预处理大鼠子宫中的速激肽受体群体。为此,我们研究了负责速激肽诱导纵向排列平滑肌层收缩的受体类型。研究了P物质(SP)、神经激肽A(NKA)、神经激肽B(NKB)及其对速激肽NK1、NK2和NK3受体具有明确选择性的几种类似物的作用,并评估了选择性非肽速激肽受体拮抗剂(S)1 -(2 - [3 -(3,4 - 二氯苯基)- 1 -(3 - 异丙氧基苯基乙酰基)哌啶 - 3 - 基]乙基)- 4 - 苯基 - 氮杂双环[2.2.2]辛烷氯化物(SR 140333,NK1选择性)、(S)- N - 甲基 - N[4 -(4 - 乙酰氨基 - 4 - 苯基哌啶基)- 2 -(3,4 - 二氯苯基)丁基]苯甲酰胺(SR 48968,NK2选择性)和(R)-(N)-(1 -(3 -(1 - 苯甲酰基 - 3 -(3,4 - 二氯苯基)哌啶 - 3 - 基)丙基)- 4 - 苯基哌啶 - 4 - 基)- N - 甲基乙酰胺(SR 142801,NK3选择性)对其的抑制作用。此外,使用逆转录 - 聚合酶链反应(RT - PCR)检测速激肽受体mRNA的表达。2 SP、NKA、[Nle10] - NKA(4 - 10)(对速激肽NK2受体类型具有选择性的类似物)和NKB引起大鼠子宫的浓度依赖性收缩。pD2值分别为5.95±0.19;6.73±0.21;7.53±0.12和5.76±0.21。速激肽NK1受体的选择性激动剂[Sar9Met(O2)11] - SP在纳摩尔浓度范围内产生小的相位反应。速激肽NK3受体选择性激动剂[MePhe7] - NKB未能诱导任何显著收缩。3 在中性内肽酶抑制剂磷酰胺素(1μM)存在下,对外源性速激肽及其类似物的对数浓度 - 反应曲线显著向左移动。SP、NKA、[Nle10] - NKA(4 - 10)和NKB的pD2值分别为6.12±0.10、8.04±0.07、7.89±0.03和6.59±0.07。在磷酰胺素(1μM)存在下,当仅将一种浓度的药物应用于每个子宫条带时,[Sar9Met(O2)11] - SP(1 nM - 0.3μM)诱导幅度增加的浓度依赖性收缩,pD2值为7.61±0.89。[MePhe7] - NKB诱导小的、不一致的收缩,因此无法计算pD2值。4 在磷酰胺素(1μM)存在下进行的实验中,SR 48968(3 nM - 0.1μM)导致NKA的对数浓度 - 反应曲线平行且向右移动。计算出的pKB值为9.16±0.08,Schild回归的斜率为1.28±0.24。SR 48968(0.1μM)也拮抗对SP的反应,表观pKB值为7.63±0.13。SR 48968(0.1μM)抑制NKB(1 nM - 3μM)和[Nle10] - NKA(4 - 10)(0.1 nM - 3μM)引起的收缩,但对[Sar9Met(O2)11] - SP(0.1μM)诱发的反应无影响。5 SR 140333(0.1μM)抑制对SP的反应,表观pKB值为7.19±0.22。该化合物对NKA、[Nle10] - NKA(4 - 10)和NKB的反应无显著影响,但抑制[Sar9Met(O2)11] - SP(0.1μM)诱导的收缩。SR 142801(0.1μM)对天然速激肽或其类似物的反应无影响。6 从功能研究中使用的一些子宫中提取总RNA。RT - PCR分析显示对应于编码速激肽NK1(587个碱基对)和NK2受体(491个碱基对)cDNA预期产物大小的单条带(n = 6只不同动物)。检测到对应于速激肽NK3受体预期325个碱基对产物的极低丰度转录本。7 目前的数据表明,在雌激素预处理的大鼠子宫中表达有功能活性的速激肽NK1和NK2受体。NK2受体类型似乎是速激肽引起的收缩反应中最重要的受体。NK3受体以痕量存在,似乎不参与速激肽诱导的收缩。